* Please place orders in Case Pack quantities

Biaxin is a registered trademark of Abbott Laboratories

Indications: Clarithromycin tablets, USP is indicated for mild to moderate infections in adults for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis; acute maxillary sinusitis (AMS) due to S. pneumoniae, H. influenzae, or M. catarrhalis; and community-acquired pneumonia (CAP) due to S. pneumoniae, C. pneumoniae (TWAR), M. pneumoniae, or H. influenzae. BIAXIN XL is also indicated for H. parainfluenzae and M. catarrhalis in CAP
Important safety information: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clarithromycin tablets, USP and other antibacterial drugs, Clarithromycin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. Clarithromycin is contraindicated in patients taking cisapride, pimozide, astemizole, or terfenadine, due to the potential for cardiac arrhythmias when taken in combination; in patients taking ergotamine or dihydroergotamine due to potential acute ergot toxicity; and in patients with a known hypersensitivity to clarithromycin or any other macrolide antibiotic. Clarithromycin may elevate digoxin serum concentrations. Serum digoxin concentrations should be carefully monitored while digoxin and clarithromycin are taken concomitantly. Clarithromycin should not be used in pregnant women except in circumstances for which no alternative therapy is appropriate. The most frequently reported adverse events for Clarithromycin tablets, USP were diarrhea (3%), nausea (3%), abnormal taste (3%), dyspepsia (2%), abdominal pain/discomfort (2%), and headache (2%). The dose of clarithromycin should be halved, or the dosing interval doubled, in patients with severe renal impairment (CrCl<30 mL/min).